STATEMENT OF STATIN: AN ANCHOR OF MEVALONATE PATHWAY

Arpita Biswas, *Dr. Dhrubo Jyoti Sen, Dr. Sudip Kumar Mandal, Dr. Shubhabrata Ray and Dr. Dhananjoy Saha

ABSTRACT

Hydroxymethylglutaryl–CoA (HMG–CoA) reductase inhibitors, also known as "statins," are used adjunctively to diet and exercise to treat hypercholesterolemia by lowering total cholesterol (TC), low–density lipoprotein cholesterol (LDL–C), and triglycerides (TG) concentrations while increasing high–density lipoprotein cholesterol (HDL–C) concentrations. The approved FDA indications vary slightly between each statin but generally are indicated for the treatment and/or prevention of primary and secondary prevention clinical atherosclerotic cardiovascular disease (ASCVD) (e.g., myocardial infarction or stroke). The choice of agent should have its basis on patient–specific characteristics, the pharmacokinetic profiles of each medication.

Keywords: Chylomicrons, VLDL, IDL, LDL, HDL, Cholesterol, HMG HMG–CoA reductase inhibitors, Statins, PCSK9 inhibitor.